Metabolic alterations in men with coronary artery disease and concomitant prostate cancer and possibilities of their correction in statin-intolerant patients

O.V. Kuryata; O.Yu.  Sirenko

doi:10.26641/2307-0404.2026.1.356898

Authors

O.V. Kuryata Dnipro State Medical University, Volodymyra Vernadskoho str., 9, Dnipro, 49044, Ukraine https://orcid.org/0000-0001-7642-0077
O.Yu. Sirenko Dnipro State Medical University, Volodymyra Vernadskoho str., 9, Dnipro, 49044, Ukraine https://orcid.org/0000-0003-4728-8614

DOI:

https://doi.org/10.26641/2307-0404.2026.1.356898

Keywords:

dyslipidemia, insulin resistance, coronary artery disease, prostate cancer survivors, statin-intolerance, ursodeoxycholic acid

Abstract

Numerous studies suggest an increased frequency of dyslipidemia and metabolic disorders in patients with prostate adenocarcinoma. The aim was to evaluate lipid profile, insulin resistance level in men with coronary artery disease and concomitant prostate cancer and impact of ursodeoxycholic acid on these indicators in complex therapy. Study included 48 men with coronary artery disease and prostate adenocarcinoma. The lipid profile, insulin resistance, testosterone level were determined in all of patients. The level of insulin, C-reactive protein were determined by immune-enzyme analysis. 1st group (n=22) was made up by statin-intolerant patients treated with ursodeoxycholic acid during 60 days in addition to standard therapy; 2nd group (n=26) – by statin-intolerant patients treated with standard regimen. The levels of triglycerides, low density lipoprotein-cholesterol and apolipoprotein-B in men with coronary artery disease and prostate adenocarcinoma were significantly higher than those in control group (p<0.001). The complex therapy with ursodeoxycholic acid resulted in significant decrease in the level of total cholesterol by 17.6% (p<0.001), triglycerides by 21.6% (p<0.001), low density lipoprotein-cholesterol by 25.2% (p<0.001), apolipoprotein-B by 12.9% (p<0.001), HOMA index level by 19.4% (p=0.001), median insulin level by 22.9% (p=0.002). Men with coronary artery disease and concomitant prostate cancer are characterized by increased levels of triglycerides, low density lipoprotein-cholesterol, insulin resistance and decreased apolipoprotein-B associated with low testosterone level. Complex treatment with ursodeoxycholic acid in these patients contributed to significant lipid level improvement and additional decrease of insulin resistance.

References

Estruch R, Ruilope LM, Cosentino F. The year in cardiovascular medicine 2020: epidemiology and preven-tion. European Heart Journal. 2021;42(8):813-21. doi: https://doi.org/10.1093/eurheartj/ehaa1062

Ralapanawa U, Sivakanesan R. Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review. J Epidemiol Glob Health. 2021;11(2):169-77. doi: https://doi.org/10.2991/jegh.k.201217.001

Vieira Lima Aguiar Melão B, Pekala K, Matsoukas K, et al. SIU-ICUD: Epidemiology of Prostate Cancer. Soc Int Urol J. 2025;6(44). doi: https://doi.org/10.3390/siuj6030044

Sun L, Parikh RB, Hubbard RA, et al. Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer. JAMA Netw Open. 2021;4(2):e210070. doi: https://doi.org/10.1001/jamanetworkopen.2021.0070

Kuryata O, Sirenko O. The Influence of L-Carnitine in the Complex Treatment of Patients With Renal Dysfunction Who Have Synchronous Chronic Coronary Artery Disease and Prostate Adenocarcinoma. Turkiye Klinikleri J Med Sci. 2019;39(4):381-8. doi: https://doi.org/10.5336/medsci.2019-65452

Kuryata OV, Sirenko O, Tykhomyrov A, et al. Plasminogen activator inhibitor-1 and circulating ceruloplasmin levels in men with iron-deficiency anemia and heart failure with concomitant prostate cancer and their dynamics after treatment. Journal of Medical Sciences. 2022;42:72-80. doi: https://doi.org/10.4103/jmedsci.jmedsci_427_20

Kim TH, Lim DG, Chung HS, Chang Hwang E, Kang TW, Kwon DD, et al. The prevalence of dyslipi-demia in patients with prostate cancer. Prostate Int. 2025;13(3):174-8. doi: https://doi.org/10.1016/j.prnil.2025.03.005

Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the mana¬gement of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal. 2025;46(42):4359-78. doi: https://doi.org/10.1093/eurheartj/ehaf190

Zhang H, Xu H, Zhang C, et al. Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis. Cell Death Discov. 2021;7(1):207. doi: https://doi.org/10.1038/s41420-021-00589-8

Lakić B, Škrbić R, Uletilović S, et al. Beneficial Effects of Ursodeoxycholic Acid on Metabolic Parameters and Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind, Placebo-Controlled Clinical Study. J Diabetes Res. 2024 Feb 29;2024:4187796. doi: https://doi.org/10.1155/2024/4187796

Daniels JP, Hernández-Tirado A, Mirocha J, et al. Association between insulin resistance and prostate volume: A 4-year analysis from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial. BJUI Compass. 2025;6(9):e70085. doi: https://doi.org/10.1002/bco2.70085

Morieri ML, Perrone V, Veronesi C, et al. Improving statin treatment strategies to reduce LDL-cho-lesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes. Cardiovasc Diabetol. 2021 Jul 16;20(1):144. doi: https://doi.org/10.1186/s12933-021-01338-y

Zeng H, Safratowich BD, Cheng W-H, et al. Ursodeoxycholic Acid Exhibits Greater Inhibitory Effects on Cancerous HCT116 Colon Cells than on Noncancerous NCM460 Colon Cells. Nutrients. 2025;17:1072. doi: https://doi.org/10.3390/nu17061072

Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55(4):622-7. doi: https://doi.org/10.1053/j.ajkd.2010.02.337

Martín García A, Mitroi C, Mazón Ramos P, et al. Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC. Rev Esp Cardiol (Engl Ed). 2021;74(5):438-48. doi: https://doi.org/10.1016/j.rec.2020.11.020

Khan A, Sarkar E, Chandra A, et al. Serum Insu-lin, Insulin-Like Growth Factor-1, Testosterone and Lipid Profile Levels in Benign Prostatic Hyperplasia and Pros-tate Cancer at Diagnosis. Cureus. 2024;16(12):e75342. doi: https://doi.org/10.7759/cureus.75342

Zhou Z, Huang Z, Zhao Y, et al. Association between low density lipoprotein cholesterol levels and prostate cancer risk in non-hypertensive middle-aged and older American men. Sci Rep. 2024;14:29096. doi: https://doi.org/10.1038/s41598-024-80190-y

Wittert G, Grossmann M. Obesity, type 2 diabetes, and testosterone in ageing men. Rev Endocr Metab Disord. 2022;23(6):1233-42.

doi: https://doi.org/10.1007/s11154-022-09746-5

Seo SH, Lee DH, Lee YS, Cho KJ, Park HJ, Lee HW, et al. Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model. Gastroenterology Report. 2022;10:goac037. doi: https://doi.org/10.1093/gastro/goac037

Oostveen RF, Kaiser Y, Hartgers ML, et al. Ursodeoxycholic Acid for Trans Intestinal Cholesterol Excretion Stimulation: A Randomized Placebo Controlled Cros¬sover Study. J Am Heart Assoc. 2024;13(20):e035259. doi: https://doi.org/10.1161/JAHA.124.035259

Reiss AB, Vasalani S, Albert J, et al. The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer. Medicina. 2024;60:1727. doi: https://doi.org/10.3390/medicina60111727

Chou E, Legasto CS, Chin AK, et al. Statin Use in Patients With Cancer: Drug Interaction and Statin Usage. JACC Adv. 2025;4(11 Pt 1):102259. doi: https://doi.org/10.1016/j.jacadv.2025.102259

Xia X, Niu H, Xu C, Liu X, Zhang G, Ling J. Revisiting the metabolic crosstalk between type 2 diabetes and hyperuricemia: Pathophysiological insights and thera¬peutic perspectives. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2026;1872(2):168102. doi: https://doi.org/10.1016/j.bbadis.2025.168102

de Jesus M, Mohammed T, Singh M, et al. Etiology and Management of Dyslipidemia in Patients With Cancer. Front Cardiovasc Med. 2022;25(9):892335. doi: https://doi.org/10.3389/fcvm.2022.892335

Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353-64. doi: https://doi.org/10.1056/NEJMoa2215024

Velez BC, Petrella CP, DiSalvo KH, et al. Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion. Oncol Rep. 2023;49(2):32. doi: https://doi.org/10.3892/or.2022.8469

Makhanets L, Vinnychuk O, Hryhorkiv M. [Statistics: Laboratory Workshop in STATISTICA 12: Tuto-rial]. Chernivtsi: Chernivets nats un-t im. Yu. Fedkovycha; 2023. 161 р. Ukrainian.

Pancholia AK, Kabra NK, Gupta R. Laboratory evaluation of lipid parameters in clinical practice. Indian Heart J. 2024;76(Suppl 1):S29-S32. doi: https://doi.org/10.1016/j.ihj.2024.02.002

Gastaldelli A. Measuring and estimating insulin resistance in clinical and research settings. Obesity (Silver Spring). 2022;30(8):1549-63. doi: https://doi.org/10.1002/oby.23503

Kwok R, Kishore K, Zafari T, et al. Comparative performance of CKD-EPI equations in people with diabetes: An international pooled analysis of individual partici-pant data. Diabetes Res Clin Pract. 2025;223:112104. doi: https://doi.org/10.1016/j.diabres.2025.112104